Publication date: Feb 05, 2019
Multiple sclerosis (MS) is a leading cause of disability in adults and requires lifelong treatment. Specialty drugs referred to as disease-modifying therapies (DMTs) have become the standard for multiple sclerosis treatment since the 1990s as they have been shown to reduce the risk of relapses and to delay disease progression. While more DMTs became available, prices of DMTs including existing drugs continue to rise and remain very expensive. This study is to estimate recent drug costs for DMTs and examine its impact on overall health care costs among individuals with MS enrolled in commercial insurance.
This study is a population-based, retrospective study using 2011-2015 IBM MarketScan(R) Commercial Database. Individuals aged
Kim, Y., Krause, T.M., Blum, P., and Freeman, L. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis. 17341. 2019 Mult Scler Relat Disord (30):
Please signin to view all article content and metadata.